Havah Therapeutics to Present at the RiseUp For Breast Cancer and Women’s Health Conference

Presentation to showcase a first-of-its-kind, mechanism-driven approach to breast cancer treatment through targeted androgen receptor (AR) agonism with HAV-088 — built on a fully integrated chain of evidence that connects drug exposure to cellular biology, local hormone metabolism within breast tissue, and measurable changes on advanced MRI biomarkers

BOULDER, Colo.–(BUSINESS WIRE)–Havah Therapeutics, a clinical-stage biopharmaceutical company pioneering androgen receptor (AR) agonist therapies for hormone receptor positive breast cancer, today announced that Professor Stephen Birrell MD, PhD, will deliver a presentation titled “HAV-088: Bending Evolution to the Will of Medicine” at the upcoming RiseUp for Breast Cancer and Women’s Health Conference in San Francisco.

Key highlights of the presentation include:

• A translational framework for “endocrine steering” of hormonally active breast tissue using HAV-088, an androgen receptor (AR) agonist
• An overview of Havah’s prospectively registered pilot, randomized controlled trial comparing HAV-088 with tamoxifen in high-risk premenopausal women with dense breasts and marked MRI background parenchymal enhancement (BPE)
• An integrated evidence chain linking drug exposure, spatial tissue biology, intracrine hormone metabolism, and imaging biomarkers

Details for the presentation are as follows:

RiseUp For Breast Cancer and Women’s Health Conference
February 19-21, 2026
Hotel Nikko, San Francisco, CA

Presentation Title: HAV-088: Bending Evolution to the Will of Medicine
Presenter: Professor Stephen Birrell, MD, PhD
Date/Time: Friday, February 20, 12:10 Pacific Time

About Havah Therapeutics

Havah Therapeutics is developing a novel therapeutic implant to treat hormonally sensitive cancers and breast conditions by leveraging the body’s natural hormone pathways. Its lead candidate, HAV-088, is a first-in-class androgen receptor agonist that combines testosterone and low-dose anastrozole in a subcutaneous implant delivering three months of continuous therapy. This approach aims to improve compliance, safety, and efficacy with fewer side effects. Havah is currently enrolling in RECAST DCIS, a Phase 2 study evaluating non-surgical treatment of ductal carcinoma in situ (DCIS) to prevent progression to breast cancer. Learn more at www.havahtx.com.

Contacts

Media Contacts:
Matthew Brewer
mb@havahtx.com

Danielle Clark-Brown
dcb@havahtx.com